Parkinson Disease (PD)NCT07302386
Exercise Management in Parkinson's Disease
A study testing Telerehabilitation in people with Parkinson Disease (PD), run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to examine the benefits that individuals with Parkinson's disease will gain from the rehabilitation program by enabling them to manage their exercise times independently using telerehabilitation method. Read more about this study
- Who is it for?
- Ages 45 to 80 years
- Conditions the study is for
- Parkinson Disease (PD)
- What is being tested?
- Telerehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Dec 2025to 2 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with Idiopathic Parkinson's Disease by a neurologist according to the UK Parkinson's Disease Association Brain Bank clinical diagnostic criteria
- H\&Y Stage I-III
- Montreal Cognitive Assessment Scale MoCA≥21
- Having the necessary technological devices to participate in telerehabilitation
- Being able to walk 100 meters
- Having at least a primary school diploma
Who cannot join
- Presence of a neurological disorder other than Parkinson's disease
- Presence of any cardiopulmonary or musculoskeletal problem that affects gait and balance
- Receiving Deep Brain Stimulation (DBS) treatment or having undergone DBS surgery in the past
- Presence of vision or hearing problems
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Marmara University
Maltepe, Istanbul, 34852
Gökçe Kartal, 05055624837, gokcekartal95@hotmail.com
About this study
Official title: The Effects of Exercise Management in Parkinson's Disease
The aim of this study is to examine the benefits that individuals with Parkinson's disease will gain from the rehabilitation program by enabling them to manage their exercise times independently using telerehabilitation method.
The main research questions examined in this study are as follows:
- Are the improvements in quality of life, walking speed and changes in functionality parameters achieved by individuals with Parkinson's disease through managing their own exercise plans as effective as those achieved through a supervised exercise programme?
- Is it effective for Parkinson's patients to manage their own exercise plans in improving their adherence to exercise?
Read the detailed description
Parkinson's Disease (PD) is a movement disorder characterized by motor and non-motor symptoms, changes in the patient's balance and gait patterns, and a significant impact on daily living activities. Physical therapy and rehabilitation play a crucial role in managing the symptoms resulting from PD. It is known that early participation in a rehabilitation program significantly improves patients' quality of life.
Patients need to incorporate exercise prescriptions designed specifically for them into their lives and participate in a lifelong exercise program. While integrating these exercises into their lives, patients encounter certain barriers and lose their motivation to exercise. These barriers can include transportation, economic problems, time management, and motor and non-motor symptoms.
Home-based exercises and telerehabilitation methods emerge as solutions for dealing with transportation, economic problems, and time management. These methods can be seen as important aids in helping patients develop the habit of exercising.
Patients diagnosed with Idiopathic Parkinson's Disease who meet the inclusion criteria and agree to participate in the study will be included. The demographic information (age, occupation, height, body weight, etc.) and clinical status (duration of diagnosis, medication dosage, etc.) of all participants will be recorded. The Montreal Cognitive Assessment Scale will be used to determine the cognitive level of patients. The motor assessment of patients will be performed using the Cognitive Parkinson's Disease Assessment Scale III. The Montreal Cognitive Assessment Scale will be used to determine the cognitive level of patients. Functional balance and mobility will be assessed using the Timed Up and Go Test and the 10-meter Walk Test. Repetitive movement performance will be assessed using the 5 Repeat Sit-to-Stand Test, and balance level will be assessed using the Activity-Specific Balance Confidence Scale. Quality of life will be assessed using the Parkinson's Disease Quality of Life Questionnaire. Motivation to exercise and self-assessment will be determined using the Behavioral Modifications to Exercise Scale-2. These assessment criteria will be re-evaluated before and after the exercise program. Patients will be given an exercise diary and asked to keep it throughout the program. The System Usability Scale will be used to evaluate the usability of the website developed for this thesis study.
Participants will be randomly assigned to 2 groups. The control group will complete the exercise program assigned to them continuously via the web-based system. The experimental group will complete the exercise program assigned to them at their preferred time within the same day. Exercise programs will be planned for 8 weeks.
- Conditions
- Parkinson Disease (PD)
- Being tested
- Telerehabilitation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TelerehabilitationOther
The exercises will consist of stretching, strengthening, balance, and neuromotor exercises that the patient can perform independently at home.
| Study group | Role | What they receive |
|---|---|---|
| Self-Management Group | Experimental | The self-management group will perform the exercise programme prescribed by the physical therapist and tailored to the patient's needs via a web-based system twice a week for eight weeks, at a time of their choosing. Receives: Other: Telerehabilitation |
| Telerehabilitation Group | Active comparator | Telerehabilitation group will perform the exercise programme prescribed by the physical therapist and tailored to the patient's needs via a web-based system twice a week for eight weeks. Receives: Other: Telerehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in motor impairment
The Unified Parkinson's Disease Rating Scale (UPDRS) is used to determine the symptoms and clinical severity of PD. The UPDRS-III subscore will be used to assess changes in motor impairment.
Measured: Baseline and the end of the 8 weeks exercise program
Change in behavioral regulations in exercise
Behavioral Regulations in Exercise Questionnaire-2 consists of 19 items and five subscales. The subscales consist of external regulation, internalized regulation, defined regulation, internal regulation and lack of motivation. It is a 5-point Likert-type scale scored between 0-4.
Measured: Baseline and the end of the 8 weeks exercise program
Change in lower extremity power and endurance
Five Times Sit to Stand Test will be used to measure repetitive movement performance. The patient will be asked to sit down and stand up 5 times as quickly as possible, and this time will be recorded in seconds.
Measured: Baseline and the end of the 8 weeks exercise program
Change in walking speed
10-Meter Walk Test will be applied to assess walking speed. The first 2 meters of the 14-meter distance are allocated for acceleration, the last 2 meters for deceleration, and the time taken to walk the 10-meter distance is recorded. Walking speed is calculated in meters per second.
Measured: Baseline and the end of the 8 weeks exercise program
Change in mobility
Timed Up and Go Test is used to assess mobility, balance, and risk of falling. The patient is asked to stand up from a chair, walk around a cone 3 meters away, and return to sit on the chair. The total time is recorded using a stopwatch.
Measured: Baseline and the end of the 8 weeks exercise program
Change in body position
Activities-Specific Balance Confidence is a measure that assesses a person's level of confidence in their balance both indoors and outdoors. It consists of 16 different activities and is rated on a scale from no confidence (-0) to complete confidence (-100). A higher score indicates a greater level of confidence in balance.
Measured: Baseline and the end of the 8 weeks exercise program
Change in quality of life
The Parkinson's Disease Quality of Life Questionnaire (PDQ-39) will be used to assess quality of life. It consists of 39 items and is composed of 8 sub-parameters: mobility, activities of daily living, stigma, social support, communication, emotional well-being, and physical discomfort. As the score increases, quality of life deteriorates.
Measured: Baseline and the end of the 8 weeks exercise program
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start15 Dec 2025
- Primary completion7 Nov 2026 (estimated)
- Study completion2 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- More trials run by Marmara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gökçe Kartal, Marmara University
- Investigators
- Semra Oğuz, PhD, Study director, Marmara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07302386
- Sponsor's protocol ID
- 949
- Status last verified
- Mar 2026
- First submitted
- 11 Dec 2025
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Franchignoni F, Giordano A, Ronconi G, Rabini A, Ferriero G. Rasch validation of the Activities-specific Balance Confidence Scale and its short versions in patients with Parkinson's disease. J Rehabil Med. 2014 Jun;46(6):532-9. doi: 10.2340/16501977-1808.
PubMed 24687205Huang SL, Hsieh CL, Wu RM, Tai CH, Lin CH, Lu WS. Minimal detectable change of the timed "up & go" test and the dynamic gait index in people with Parkinson disease. Phys Ther. 2011 Jan;91(1):114-21. doi: 10.2522/ptj.20090126. Epub 2010 Oct 14.
PubMed 20947672Dean CM, Richards CL, Malouin F. Walking speed over 10 metres overestimates locomotor capacity after stroke. Clin Rehabil. 2001 Aug;15(4):415-21. doi: 10.1191/026921501678310216.
PubMed 11518442Duncan RP, Leddy AL, Earhart GM. Five times sit-to-stand test performance in Parkinson's disease. Arch Phys Med Rehabil. 2011 Sep;92(9):1431-6. doi: 10.1016/j.apmr.2011.04.008.
PubMed 21878213Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198.
PubMed 17115387Fahn S. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease. 1987:153-63.
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10.
PubMed 33848468
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Exercise Management in Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07302386
- Acronym / sponsor ID
- 949
- Conditions
- Parkinson Disease (PD)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 15 Dec 2025 (actual)
- Primary completion
- 7 Nov 2026 (estimated)
- Study completion
- 2 Dec 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to examine the benefits that individuals with Parkinson's disease will gain from the rehabilitation program by enabling them to manage their exercise times independently using telerehabilitation method.
The main research questions examined in this study are as follows:
- Are the improvements in quality of life, walking speed and changes in functionality parameters achieved by individuals with Parkinson's disease through managing their own exercise plans as effective as those achieved through a supervised exercise programme?
- Is it effective for Parkinson's patients to manage their own exercise plans in improving their adherence to exercise?
Detailed description
Parkinson's Disease (PD) is a movement disorder characterized by motor and non-motor symptoms, changes in the patient's balance and gait patterns, and a significant impact on daily living activities. Physical therapy and rehabilitation play a crucial role in managing the symptoms resulting from PD. It is known that early participation in a rehabilitation program significantly improves patients' quality of life.
Patients need to incorporate exercise prescriptions designed specifically for them into their lives and participate in a lifelong exercise program. While integrating these exercises into their lives, patients encounter certain barriers and lose their motivation to exercise. These barriers can include transportation, economic problems, time management, and motor and non-motor symptoms.
Home-based exercises and telerehabilitation methods emerge as solutions for dealing with transportation, economic problems, and time management. These methods can be seen as important aids in helping patients develop the habit of exercising.
Patients diagnosed with Idiopathic Parkinson's Disease who meet the inclusion criteria and agree to participate in the study will be included. The demographic information (age, occupation, height, body weight, etc.) and clinical status (duration of diagnosis, medication dosage, etc.) of all participants will be recorded. The Montreal Cognitive Assessment Scale will be used to determine the cognitive level of patients. The motor assessment of patients will be performed using the Cognitive Parkinson's Disease Assessment Scale III. The Montreal Cognitive Assessment Scale will be used to determine the cognitive level of patients. Functional balance and mobility will be assessed using the Timed Up and Go Test and the 10-meter Walk Test. Repetitive movement performance will be assessed using the 5 Repeat Sit-to-Stand Test, and balance level will be assessed using the Activity-Specific Balance Confidence Scale. Quality of life will be assessed using the Parkinson's Disease Quality of Life Questionnaire. Motivation to exercise and self-assessment will be determined using the Behavioral Modifications to Exercise Scale-2. These assessment criteria will be re-evaluated before and after the exercise program. Patients will be given an exercise diary and asked to keep it throughout the program. The System Usability Scale will be used to evaluate the usability of the website developed for this thesis study.
Participants will be randomly assigned to 2 groups. The control group will complete the exercise program assigned to them continuously via the web-based system. The experimental group will complete the exercise program assigned to them at their preferred time within the same day. Exercise programs will be planned for 8 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Self-Management Group | Experimental | Other: TelerehabilitationThe self-management group will perform the exercise programme prescribed by the physical therapist and tailored to the patient's needs via a web-based system twice a week for eight weeks, at a time of their choosing. |
| Telerehabilitation Group | Active comparator | Other: TelerehabilitationTelerehabilitation group will perform the exercise programme prescribed by the physical therapist and tailored to the patient's needs via a web-based system twice a week for eight weeks. |
Who may qualify
- Ages
- 45 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosed with Idiopathic Parkinson's Disease by a neurologist according to the UK Parkinson's Disease Association Brain Bank clinical diagnostic criteria
- H\&Y Stage I-III
- Montreal Cognitive Assessment Scale MoCA≥21
- Having the necessary technological devices to participate in telerehabilitation
- Being able to walk 100 meters
Key exclusion criteria (4 listed)
- Presence of a neurological disorder other than Parkinson's disease
- Presence of any cardiopulmonary or musculoskeletal problem that affects gait and balance
- Receiving Deep Brain Stimulation (DBS) treatment or having undergone DBS surgery in the past
- Presence of vision or hearing problems
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TelerehabilitationThe exercises will consist of stretching, strengthening, balance, and neuromotor exercises that the patient can perform independently at home. | Other | Self-Management Group, Telerehabilitation Group |
Primary outcome
Change in motor impairment
Time frame: Baseline and the end of the 8 weeks exercise program
The Unified Parkinson's Disease Rating Scale (UPDRS) is used to determine the symptoms and clinical severity of PD. The UPDRS-III subscore will be used to assess changes in motor impairment.
Change in behavioral regulations in exercise
Time frame: Baseline and the end of the 8 weeks exercise program
Behavioral Regulations in Exercise Questionnaire-2 consists of 19 items and five subscales. The subscales consist of external regulation, internalized regulation, defined regulation, internal regulation and lack of motivation. It is a 5-point Likert-type scale scored between 0-4.
Change in lower extremity power and endurance
Time frame: Baseline and the end of the 8 weeks exercise program
Five Times Sit to Stand Test will be used to measure repetitive movement performance. The patient will be asked to sit down and stand up 5 times as quickly as possible, and this time will be recorded in seconds.
Change in walking speed
Time frame: Baseline and the end of the 8 weeks exercise program
10-Meter Walk Test will be applied to assess walking speed. The first 2 meters of the 14-meter distance are allocated for acceleration, the last 2 meters for deceleration, and the time taken to walk the 10-meter distance is recorded. Walking speed is calculated in meters per second.
Change in mobility
Time frame: Baseline and the end of the 8 weeks exercise program
Timed Up and Go Test is used to assess mobility, balance, and risk of falling. The patient is asked to stand up from a chair, walk around a cone 3 meters away, and return to sit on the chair. The total time is recorded using a stopwatch.
Change in body position
Time frame: Baseline and the end of the 8 weeks exercise program
Activities-Specific Balance Confidence is a measure that assesses a person's level of confidence in their balance both indoors and outdoors. It consists of 16 different activities and is rated on a scale from no confidence (-0) to complete confidence (-100). A higher score indicates a greater level of confidence in balance.
Change in quality of life
Time frame: Baseline and the end of the 8 weeks exercise program
The Parkinson's Disease Quality of Life Questionnaire (PDQ-39) will be used to assess quality of life. It consists of 39 items and is composed of 8 sub-parameters: mobility, activities of daily living, stigma, social support, communication, emotional well-being, and physical discomfort. As the score increases, quality of life deteriorates.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- Background: PubMed 24687205Franchignoni F, Giordano A, Ronconi G, Rabini A, Ferriero G. Rasch validation of the Activities-specific Balance Confidence Scale and its short versions in patients with Parkinson's disease. J Rehabil Med. 2014 Jun;46(6):532-9. doi: 10.2340/16501977-1808.
- Background: PubMed 20947672Huang SL, Hsieh CL, Wu RM, Tai CH, Lin CH, Lu WS. Minimal detectable change of the timed "up & go" test and the dynamic gait index in people with Parkinson disease. Phys Ther. 2011 Jan;91(1):114-21. doi: 10.2522/ptj.20090126. Epub 2010 Oct 14.
- Background: PubMed 11518442Dean CM, Richards CL, Malouin F. Walking speed over 10 metres overestimates locomotor capacity after stroke. Clin Rehabil. 2001 Aug;15(4):415-21. doi: 10.1191/026921501678310216.
- Background: PubMed 21878213Duncan RP, Leddy AL, Earhart GM. Five times sit-to-stand test performance in Parkinson's disease. Arch Phys Med Rehabil. 2011 Sep;92(9):1431-6. doi: 10.1016/j.apmr.2011.04.008.
- Background: PubMed 17115387Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198.
- BackgroundFahn S. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease. 1987:153-63.
- Background: PubMed 33848468Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease (PD)
Enrolling by invitation
Effect of Hand Rehabilitation on Cognitive Function in Patients With PD
PARKINSON DISEASE (Disorder)
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
RecruitingPhase 2
A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease
Parkinson Disease
RecruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
AAV2-hAADC for Parkinson's Disease (PDCS-01)
Parkinson's Disease (PD), Early Onset Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Semra Oğuz, PhD study director
Marmara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Telerehabilitation in people with Parkinson Disease (PD), run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gökçe Kartal (+905055624837, gokcekrtl2@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in motor impairment (time frame: Baseline and the end of the 8 weeks exercise program). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07302386, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.